Ivosidenib

The Basics

What is Ivosidenib?

Used to treat acute myeloid leukemia-AML.

Brand names for Ivosidenib

N/A

How Ivosidenib is classified

Antineoplastic Agents, Enzyme Inhibitors, Protein Kinase Inhibitors, Signal Transduction Inhibitors, Isocitrate Dehydrogenase Inhibitors

Ivosidenib During Pregnancy

Ivosidenib pregnancy category

Category N/ANote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Ivosidenib while pregnant

N/A

Taking Ivosidenib While Breastfeeding

What are recommendations for lactation if you're taking Ivosidenib?

No information is available on the clinical use of ivosidenib during breastfeeding. Because ivosidenib is 92 to 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 93 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 1 month after the dose.

Maternal / infant drug levels

No information is available on the clinical use of ivosidenib during breastfeeding. Because ivosidenib is 92 to 96% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 93 hours and it might accumulate in the infant. The manufacturer recommends that breastfeeding be discontinued during erlotinib therapy and for 1 month after the dose.

Possible effects of Ivosidenib on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Ivosidenib

None listed